{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:19:54Z","timestamp":1781767194160,"version":"3.54.5"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swiss National Foundation"},{"name":"University Hospital Basel, Switzerland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 (GLP-1) plays an important modulatory role in sodium and water homeostasis. Recent studies demonstrated that long-term treatment with GLP-1 receptor agonists (RAs) reduces fluid intake and urine output. To the best of our knowledge, no direct effect of GLP-1 on vasopressin has been observed. This secondary analysis aimed to investigate changes in copeptin levels in euvolemic participants treated with the GLP-1 RA dulaglutide versus placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Secondary analysis of two randomized, double-blind, placebo-controlled, cross-over trials in 34 patients with primary polydipsia and 20 healthy participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants received a 3-week intervention with dulaglutide (Trulicity) 1.5\u2005mg or placebo (.9% sodium chloride) subcutaneously once weekly. Blood for copeptin analysis was collected at 08:00 after each treatment phase. To estimate the treatment effect of dulaglutide, we derived the absolute within-subject differences of copeptin between dulaglutide and placebo and used the Wilcoxon rank test for statistical analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All 54 participants of the two cross-over trials were included. Median age was 27 years [interquartile range (IQR), 24\u201337.5 years], and 63% were female. Median body mass index (BMI) was 23\u2005kg\/m2 (IQR, 20.8\u201324.8). After 3-week treatment, dulaglutide was associated with a significant suppression of copeptin with a median within-subject difference of \u2212.7\u2005pmol\/L (p = .047), corresponding to a 12% reduction compared to placebo. Treatment-induced changes in copeptin were not significantly correlated with GLP-1\u2013mediated reductions in blood pressure, BMI, or incidence of nausea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our analysis provides evidence that the GLP-1-RA dulaglutide inhibits the vasopressin system and proposes physiological mechanisms that may explain the role of GLP-1 in sodium and water balance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvag005","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:40:19Z","timestamp":1767876019000},"page":"91-101","source":"Crossref","is-referenced-by-count":5,"title":["Effects of GLP-1 receptor agonists on copeptin in euvolemic participants"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2643-0111","authenticated-orcid":false,"given":"Svenja","family":"Leibnitz","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University of Basel, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8305-2700","authenticated-orcid":false,"given":"Bettina","family":"Winzeler","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Basel, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Z\u00fcrich , Z\u00fcrich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3040-4685","authenticated-orcid":false,"given":"Julie","family":"Refardt","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Basel, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center Rotterdam , Rotterdam 3015 GD, The \u00a0","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0668-5675","authenticated-orcid":false,"given":"Deborah R","family":"Vogt","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Basel, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6439-8191","authenticated-orcid":false,"given":"Clara O","family":"Sailer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University of Basel, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-0965","authenticated-orcid":false,"given":"Mirjam","family":"Christ-Crain","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]},{"name":"Department of Clinical Research, University of Basel, University Hospital Basel , Basel 4031 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2026030204013642400_lvag005-B1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/5584_2020_496","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"2026030204013642400_lvag005-B2","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1038\/s41591-024-03380-1","article-title":"Seven unanswered questions about blockbuster weight-loss drugs","volume":"30","author":"May","year":"2024","journal-title":"Nat Med"},{"issue":"20","key":"2026030204013642400_lvag005-B3","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJM199205143262003","article-title":"Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus","volume":"326","author":"Gutniak","year":"1992","journal-title":"N Engl J Med"},{"issue":"5","key":"2026030204013642400_lvag005-B4","doi-asserted-by":"publisher","first-page":"R1541","DOI":"10.1152\/ajpregu.1999.276.5.R1541","article-title":"Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2","volume":"276","author":"Gutzwiller","year":"1999","journal-title":"Am J Physiol"},{"issue":"2","key":"2026030204013642400_lvag005-B5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2337\/diab.47.2.159","article-title":"Glucagon-like peptides","volume":"47","author":"Drucker","year":"1998","journal-title":"Diabetes"},{"key":"2026030204013642400_lvag005-B6","first-page":"389","article-title":"Brain-gut peptides and the control of food intake","volume":"28","author":"Smith","year":"1981","journal-title":"Adv Biochem Psychopharmacol."},{"issue":"3","key":"2026030204013642400_lvag005-B7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11154-014-9287-7","article-title":"Effects of GLP-1 in the kidney","volume":"15","author":"Skov","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"2026030204013642400_lvag005-B8","doi-asserted-by":"publisher","first-page":"E664\u2013","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026030204013642400_lvag005-B9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/dom.12651","article-title":"Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial","volume":"18","author":"Skov","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2026030204013642400_lvag005-B10","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2026030204013642400_lvag005-B11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/dom.13223","article-title":"Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: post-hoc analyses of four clinical trials","volume":"20","author":"Tonneijck","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"2-3","key":"2026030204013642400_lvag005-B12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000094334","article-title":"Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans","volume":"73","author":"Gutzwiller","year":"2006","journal-title":"Digestion"},{"issue":"2","key":"2026030204013642400_lvag005-B13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12020-020-02394-2","article-title":"Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers","volume":"70","author":"Winzeler","year":"2020","journal-title":"Endocrine"},{"issue":"20","key":"2026030204013642400_lvag005-B14","doi-asserted-by":"publisher","first-page":"e151800","DOI":"10.1172\/JCI151800","article-title":"A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia","volume":"131","author":"Winzeler","year":"2021","journal-title":"J Clin Invest"},{"issue":"1","key":"2026030204013642400_lvag005-B15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1134\/S0012496614060027","article-title":"Stimulation of glucagon-like peptide-1 secretion by water loading in human","volume":"459","author":"Marina","year":"2014","journal-title":"Dokl Biol Sci"},{"issue":"4","key":"2026030204013642400_lvag005-B16","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"1","key":"2026030204013642400_lvag005-B17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s0306-4522(96)00434-4","article-title":"Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem","volume":"77","author":"Larsen","year":"1997","journal-title":"Neuroscience"},{"issue":"10","key":"2026030204013642400_lvag005-B18","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1210\/endo.138.10.5270","article-title":"Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat","volume":"138","author":"Larsen","year":"1997","journal-title":"Endocrinology"},{"issue":"3-4","key":"2026030204013642400_lvag005-B19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jchemneu.2008.07.009","article-title":"Distribution of glucagon-like peptide-1 immunoreactivity in the hypothalamic paraventricular and supraoptic nuclei","volume":"36","author":"Tauchi","year":"2008","journal-title":"J Chem Neuroanat"},{"issue":"6","key":"2026030204013642400_lvag005-B20","doi-asserted-by":"publisher","first-page":"R1755\u2013","DOI":"10.1152\/ajpregu.00472.2011","article-title":"Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake","volume":"301","author":"Mckay","year":"2011","journal-title":"Am J Physiol\u2014Regul Integr Comp Physiol"},{"issue":"49","key":"2026030204013642400_lvag005-B21","doi-asserted-by":"publisher","first-page":"16417","DOI":"10.1523\/JNEUROSCI.3267-14.2014","article-title":"Endogenous glucagon-like peptide-1 reduces drinking behavior and is differentially engaged by water and food intakes in rats","volume":"34","author":"McKay","year":"2014","journal-title":"J Neurosci"},{"issue":"4","key":"2026030204013642400_lvag005-B22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1159\/000484152","article-title":"Effect of salt intake on serum glucagon-like peptide-1 levels in normotensive salt-sensitive subjects","volume":"42","author":"Zheng","year":"2017","journal-title":"Kidney Blood Press Res"},{"issue":"15","key":"2026030204013642400_lvag005-B23","doi-asserted-by":"publisher","first-page":"e14519","DOI":"10.14814\/phy2.14519","article-title":"Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP-1 but not GIP, CCK, and gastrin in plasma","volume":"8","author":"Asmar","year":"2020","journal-title":"Physiol Rep"},{"issue":"8","key":"2026030204013642400_lvag005-B24","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.3390\/ijms22083951","article-title":"NFAT5 is involved in GRP-enhanced secretion of GLP-1 by sodium","volume":"22","author":"Fan","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2026030204013642400_lvag005-B25","doi-asserted-by":"publisher","first-page":"F355\u2013","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol\u2014Ren Physiol"},{"issue":"7","key":"2026030204013642400_lvag005-B26","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1210\/jc.2019-00004","article-title":"Extracellular fluid volume expansion uncovers a natriuretic action of GLP-1: a functional GLP-1-renal axis in man","volume":"104","author":"Asmar","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026030204013642400_lvag005-B27","doi-asserted-by":"publisher","first-page":"e2581","DOI":"10.1210\/clinem\/dgac063","article-title":"Effect of a 3-week treatment with GLP-1 receptor agonists on vasoactive hormones in euvolemic participants","volume":"107","author":"Vukajlovic","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026030204013642400_lvag005-B28","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.2337\/dc16-1371","article-title":"Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial","volume":"39","author":"Tonneijck","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"2026030204013642400_lvag005-B29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11154-019-09509-9","article-title":"Vasopressin and Copeptin in health and disease","volume":"20","author":"Christ-Crain","year":"2019","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"2026030204013642400_lvag005-B30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1258\/000456307781646030","article-title":"Vasopressin and disorders of water balance: the physiology and pathophysiology of vasopressin","volume":"44","author":"Ball","year":"2007","journal-title":"Ann Clin Biochem"},{"issue":"Suppl 2","key":"2026030204013642400_lvag005-B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000488233","article-title":"Vasopressin and the regulation of thirst","volume":"72","author":"Bichet","year":"2018","journal-title":"Ann Nutr Metab"},{"issue":"1","key":"2026030204013642400_lvag005-B32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1046\/j.1471-4159.1999.0720010.x","article-title":"Coexpression of glucagon-like peptide-1 (GLP-1) receptor, vasopressin, and oxytocin mRNAs in neurons of the rat hypothalamic supraoptic and paraventricular nuclei: effect of GLP-1(7-36)amide on vasopressin and oxytocin release","volume":"72","author":"Zueco","year":"1999","journal-title":"J Neurochem"},{"key":"2026030204013642400_lvag005-B33","doi-asserted-by":"publisher","first-page":"101692","DOI":"10.1016\/j.molmet.2023.101692","article-title":"Osmoadaptive GLP-1R signalling in hypothalamic neurones inhibits antidiuretic hormone synthesis and release","volume":"70","author":"Greenwood","year":"2023","journal-title":"Mol Metab"},{"issue":"17","key":"2026030204013642400_lvag005-B34","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1113\/JP272053","article-title":"Role of enteroendocrine L-cells in arginine vasopressin-mediated inhibition of colonic anion secretion","volume":"594","author":"Pais","year":"2016","journal-title":"J Physiol"},{"key":"2026030204013642400_lvag005-B35","doi-asserted-by":"publisher","first-page":"114093","DOI":"10.1016\/j.physbeh.2023.114093","article-title":"The role of glucagon-like peptide-1 (GLP-1) in fluid and food intakes in vasopressin-deficient Brattleboro rats","volume":"262","author":"Brakey","year":"2023","journal-title":"Physiol Behav"},{"key":"2026030204013642400_lvag005-B36","doi-asserted-by":"publisher","first-page":"102072","DOI":"10.1016\/j.molmet.2024.102072","article-title":"Intestinal butyric acid-mediated disruption of gut hormone secretion and lipid metabolism in vasopressin receptor-deficient mice","volume":"91","author":"Harada","year":"2025","journal-title":"Mol Metab"},{"issue":"5","key":"2026030204013642400_lvag005-B37","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s11102-024-01451-7","article-title":"GLP-1 receptor agonists may enhance the effects of desmopressin in individuals with AVP deficiency: a case series and proposed mechanism","volume":"27","author":"Nakhleh","year":"2024","journal-title":"Pituitary"},{"issue":"4","key":"2026030204013642400_lvag005-B38","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1210\/jc.2010-2499","article-title":"Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states","volume":"96","author":"Balanescu","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026030204013642400_lvag005-B39","doi-asserted-by":"publisher","first-page":"10104","DOI":"10.1038\/s41598-021-89505-9","article-title":"Validity of different copeptin assays in the differential diagnosis of the polyuria-polydipsia syndrome","volume":"11","author":"Sailer","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"2026030204013642400_lvag005-B40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin Chem"},{"issue":"5","key":"2026030204013642400_lvag005-B41","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.diabet.2017.05.009","article-title":"Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy","volume":"43","author":"Nakatani","year":"2017","journal-title":"Diabetes Metab"},{"issue":"1-3","key":"2026030204013642400_lvag005-B42","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.regpep.2006.12.016","article-title":"Glucagon-like peptide\u202f1 receptor expression in primary porcine proximal tubular cells","volume":"141","author":"Schlatter","year":"2007","journal-title":"Regul Pept"},{"issue":"2","key":"2026030204013642400_lvag005-B43","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/dom.12601","article-title":"Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men","volume":"18","author":"Muskiet","year":"2016","journal-title":"Diabetes Obes Metab."},{"issue":"7","key":"2026030204013642400_lvag005-B44","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z","article-title":"Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial","volume":"59","author":"Tonneijck","year":"2016","journal-title":"Diabetologia"},{"issue":"6","key":"2026030204013642400_lvag005-B45","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3390\/medicina60060908","article-title":"Influence of dulaglutide on Serum biomarkers of atherosclerotic plaque instability: an interventional analysis of cytokine profiles in diabetic subjects\u2014a pilot study","volume":"60","author":"Hachu\u0142a","year":"2024","journal-title":"Medicina (B Aires)."},{"issue":"11","key":"2026030204013642400_lvag005-B46","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1111\/dom.14135","article-title":"The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes","volume":"22","author":"Nielsen","year":"2020","journal-title":"Diabetes Obes Metab."},{"issue":"6","key":"2026030204013642400_lvag005-B47","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/dom.12884","article-title":"Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial","volume":"19","author":"von Scholten","year":"2017","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"2026030204013642400_lvag005-B48","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1530\/EC-17-0327","article-title":"Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS","volume":"7","author":"Fr\u00f8ssing","year":"2018","journal-title":"Endocr Connect"},{"issue":"4","key":"2026030204013642400_lvag005-B49","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026030204013642400_lvag005-B50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag005\/66379167\/lvag005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/194\/2\/91\/66379167\/lvag005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/194\/2\/91\/66379167\/lvag005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:01:43Z","timestamp":1772442103000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/194\/2\/91\/8423044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag005","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,12]]}}}